がんナノテクノロジー市場- 世界の産業規模、シェア、動向、機会、予測、セグメント、タイプ別、用途別、エンドユーザー別、地域別、競合、2020年～2030年

がんナノテクノロジーの世界市場規模は2024年に348億米ドル、予測期間中のCAGRは9.35%で2030年には588億5,000万米ドルに達すると予測されています。

世界のがんナノテクノロジー市場は、ナノテクノロジーの進歩、より効果的ながん治療に対する需要の高まり、研究開発（R&D）への投資の増加などに後押しされ、力強い成長を遂げています。この市場には、診断ツール、標的ドラッグデリバリー、イメージング、治療など、治療結果の改善と副作用の最小化に焦点を当てた多様な用途が含まれます。ナノ粒子は、治療効果の向上と副作用の最小化を期待して、健康な組織へのダメージを減らしながら腫瘍細胞に直接薬剤を送達するよう設計されています。ナノセンサーやナノプローブといったナノテクノロジーに基づく診断ツールは、早期がん発見のために開発されており、タイムリーな介入を可能にすることで生存率を大幅に向上させる。政府機関も非公開会社もナノテクノロジーに多額の投資を行い、調査を加速させ、イノベーションをいち早く市場に投入しています。

しかし、ナノ医薬品の規制当局による承認プロセスは依然として厳格で時間がかかるため、人体内でのナノ粒子の長期的な安全性に関する懸念とともに、市場成長の課題となっています。また、ナノテクノロジーに基づく治療法の研究開発と臨床試験にかかるコストが高いことも、進歩のペースと市場参入を制限しています。画像診断では、ナノ粒子はMRI、CT、PETスキャンなどの技術に使用され、がん組織をより正確に検出し、早期診断のための造影剤として機能します。北米ががんナノテクノロジー市場をリードしているのは、強力なヘルスケア・インフラ、高い研究開発投資、バイオテクノロジーと製薬セクターの有力企業に支えられているからです。

研究が進み、新たな治療オプションが出現するにつれて、がんナノテクノロジー市場は臨床および商業用途で広く採用されることが予想されます。さらに、標的薬物送達のためのナノロボット、正確ながん細胞ターゲティングのためのスマートナノ粒子、診断と治療を組み合わせた統合ナノテクノロジーなどのイノベーションが、市場の進化をさらに促進するであろう。

主要市場促進要因

精密医療の進歩

早期発見と診断

低侵襲治療

主な市場課題

生体適合性と毒性に関する懸念

製造プロセスの標準化

主要市場動向

免疫療法の強化

多機能ナノ粒子

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のがんナノテクノロジー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（ナノ粒子、ナノファイバー、ナノロッド、グラフェン、ナノ流体デバイス、その他）
  • 用途別（乳がん、胃がん、肺がん、その他）
  • エンドユーザー別（診断、治療、セラノスティクス）
  • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
  • 企業別（2024）
• 市場マップ
• タイプ別
• 用途別
• エンドユーザー別
• 地域別

第6章 北米のがんナノテクノロジー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のがんナノテクノロジー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のがんナノテクノロジー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のがんナノテクノロジー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのがんナノテクノロジー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 世界のがんナノテクノロジー市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Abbott Laboratories Ltd.
• GE Healthcare Inc.
• Combimatrix Corporation.
• Mallinckrodt Plc
• Sigma-Tau Pharmaceuticals Inc.
• Merck and Company Inc.
• Pfizer, Inc.
• Nanosphere, Inc.（Luminex Corporation）
• Celgene Corporation
• Teva Pharmaceutical Industries

第16章 戦略的提言

Global Cancer Nanotechnology Market was valued at USD 34.80 Billion in 2024 and is expected to reach USD 58.85 Billion by 2030 with a CAGR of 9.35% during the forecast period. The global cancer nanotechnology market is experiencing robust growth, fueled by advancements in nanotechnology, the rising demand for more effective cancer treatments, and increasing investments in research and development (R&D). This market includes a diverse range of applications such as diagnostic tools, targeted drug delivery, imaging, and therapy, all focused on improving treatment outcomes and minimizing side effects. Nanoparticles are being engineered to deliver drugs directly to tumor cells, reducing damage to healthy tissues, with the expectation of enhancing therapeutic effectiveness and minimizing adverse effects. Nanotechnology-based diagnostic tools, like nanosensors and nanoprobes, are being developed for early-stage cancer detection, significantly improving survival rates by enabling timely intervention. Both government agencies and private companies are investing heavily in cancer nanotechnology, accelerating research and bringing innovations to the market faster.

However, regulatory approval processes for nanomedicines remain rigorous and time-consuming, posing challenges to market growth, along with concerns regarding the long-term safety of nanoparticles in the human body. The high costs of R&D and clinical trials for nanotechnology-based therapies also limit the pace of progress and market entry. In imaging, nanoparticles are used in technologies such as MRI, CT, and PET scans to detect cancerous tissue with greater precision and serve as contrast agents for early diagnosis. North America leads the cancer nanotechnology market, supported by a strong healthcare infrastructure, high R&D investment, and prominent players in the biotechnology and pharmaceutical sectors.

As research advances and new therapeutic options emerge, the market for cancer nanotechnology is expected to see widespread adoption across clinical and commercial applications. Additionally, innovations such as nanorobots for targeted drug delivery, smart nanoparticles for precise cancer cell targeting, and integrated nanotechnologies combining diagnostics and therapy will further drive the market's evolution.

Key Market Drivers

Precision Medicine Advancements

Precision medicine advancements are poised to propel the growth of the Global Cancer Nanotechnology Market by revolutionizing cancer treatment strategies. As precision medicine tailors medical decisions and interventions to individual patient characteristics, nanotechnology emerges as a pivotal player in enhancing targeted therapies. Nanoparticles, with their unique properties, enable precise drug delivery to cancer cells while minimizing damage to healthy tissues. This targeted approach enhances treatment efficacy and reduces side effects, aligning with the personalized nature of precision medicine. The synergy between precision medicine and cancer nanotechnology opens new avenues for innovative therapies, diagnostics, and imaging techniques. Companies investing in research and development at this intersection are likely to gain a competitive edge, driving market expansion. Moreover, the ability of nanotechnology to overcome biological barriers, optimize drug pharmacokinetics, and enable early cancer detection positions it as a cornerstone technology in the evolving landscape of cancer care. Consequently, the Global Cancer Nanotechnology Market is expected to witness significant growth, propelled by the symbiotic relationship between precision medicine advancements and the transformative potential of nanotechnology in cancer treatment.

Early Detection and Diagnosis

Early detection and diagnosis will be key drivers of growth in the Global Cancer Nanotechnology Market. Nanotechnology plays a pivotal role in developing advanced diagnostic tools that enable the detection of cancer at its nascent stages, enhancing the effectiveness of treatment interventions. Nanoparticles can be engineered to interact specifically with cancer biomarkers, facilitating highly sensitive and accurate diagnostic tests. This precision in early detection not only improves patient outcomes but also reduces overall healthcare costs associated with advanced-stage cancer treatment. Moreover, nanotechnology contributes to the development of cutting-edge imaging technologies, such as nanoparticle-based contrast agents for high-resolution imaging. These advancements enable clinicians to visualize and diagnose tumors with greater accuracy.

According to a report from the American Cancer Society, it is projected that in 2025, there will be 42,240 new cases of liver cancer diagnosed in the U.S., with 30,090 resulting in death. The two most prevalent types of liver cancer are hepatocellular carcinoma (HCC), accounting for 70% of cases, and intrahepatic bile duct cancer (cholangiocarcinoma), making up 21%. Notably, the incidence of liver cancer is nearly three times higher in men than in women. Over the past 40 years, the rate of liver cancer diagnoses has tripled, and while the incidence has continued to rise by 2% annually among women from 2017 to 2022, it has remained stable among men. These statistics highlight the critical need for improved early detection and diagnosis of liver cancer, as early-stage identification can significantly improve treatment outcomes and survival rates. Advances in cancer nanotechnology, particularly in the development of diagnostic tools such as nanosensors and nanoprobes, could offer the potential to detect liver cancer at its earliest stages, even before symptoms appear. This would be a pivotal step in addressing the rising incidence of liver cancer and providing more effective treatment options for patients.

As healthcare systems worldwide prioritize early cancer detection for improved prognosis, the demand for innovative nanotechnology solutions is set to surge. Companies investing in research and commercialization of nanotech-driven diagnostic tools are positioned to capitalize on this growing market trend, fostering the expansion of the Global Cancer Nanotechnology Market in response to the global imperative for early cancer detection and diagnosis.

Minimally Invasive Therapies

The growth of the Global Cancer Nanotechnology Market is poised to be significantly driven by the integration of minimally invasive therapies. Nanotechnology offers groundbreaking solutions for designing minimally invasive cancer treatments that enhance precision and reduce the invasiveness of procedures. Nanoparticles can be engineered to carry therapeutic agents directly to cancer cells, enabling targeted drug delivery without affecting surrounding healthy tissues. This targeted approach minimizes side effects and enhances the overall safety profile of cancer therapies. Furthermore, nanotechnology contributes to the development of theranostic platforms, combining therapy and diagnostics in a single system. This allows for real-time monitoring of treatment efficacy, optimizing therapeutic interventions for individual patients. The shift towards minimally invasive techniques aligns with the growing emphasis on patient-centric care, driving the adoption of nanotechnology-driven therapies. Companies at the forefront of developing minimally invasive cancer treatments based on nanotechnology are poised for significant market growth, as healthcare providers and patients increasingly seek alternatives to traditional, more invasive approaches. In November 2024, new advancements in nanotechnology from AIBN labs could significantly improve the effectiveness of an emerging, minimally invasive cancer treatment. Photothermal therapy (PTT), a growing method of cancer treatment, uses near-infrared light to generate heat that destroys cancer cells. In the journal Advanced Functional Materials, researchers described how their hypochlorous acid-responsive theranostic nanoprobe enables real-time cancer detection and monitoring of inflammation during PTT. This innovative theranostic nanoprobe system not only enhances cancer diagnosis but also supports the efficacy of non-invasive treatments, further improving patient outcomes by providing precise and less invasive therapeutic options. As the demand for effective and patient-friendly cancer treatments rises, the Global Cancer Nanotechnology Market is expected to flourish, propelled by innovations in minimally invasive therapies.

Key Market Challenges

Biocompatibility and Toxicity Concerns

Biocompatibility and toxicity concerns pose significant obstacles to the growth of the Global Cancer Nanotechnology Market. While nanotechnology holds immense promise in cancer treatment, the potential risks associated with the interaction of nanoparticles with biological systems raise apprehensions among researchers, regulatory bodies, and healthcare providers. Ensuring the biocompatibility of nanomaterials is crucial to prevent adverse effects on normal cells and tissues. Toxicity concerns stem from the intricate interactions between nanoparticles and biological entities, raising questions about the long-term safety of these materials. Uncertainties regarding the potential accumulation of nanoparticles in vital organs and their systemic impact on the human body create regulatory challenges and may impede market expansion. Rigorous testing and comprehensive studies are imperative to address these concerns and gain regulatory approvals. Companies operating in the Global Cancer Nanotechnology Market need to invest significantly in research and development to mitigate biocompatibility and toxicity issues. Proactive engagement with regulatory agencies to establish safety standards and transparent communication regarding risk mitigation strategies will be vital. Addressing these concerns head-on is essential for building trust among stakeholders and unlocking the full potential of nanotechnology in cancer treatment, fostering sustainable market growth.

Standardization of Manufacturing Processes

The standardization of manufacturing processes poses a potential hindrance to the growth of the Global Cancer Nanotechnology Market. The inherent complexity of nanotechnology, with its varied materials and intricate fabrication methods, makes standardization challenging. Unlike traditional pharmaceuticals, nanomedicines often require specialized manufacturing techniques tailored to specific formulations, hindering the development of standardized processes. The dynamic nature of nanomaterials and their diverse applications in cancer treatment demand flexibility in manufacturing, as one-size-fits-all approaches may limit innovation and customization. Attempts to impose rigid standards could stifle the creativity and adaptability required for continuous advancements in nanotechnology. Moreover, the regulatory landscape for nanomedicines is still evolving, further complicating efforts to establish universally applicable manufacturing standards. Companies in the Global Cancer Nanotechnology Market must navigate these challenges by advocating for flexible regulatory frameworks that accommodate the unique characteristics of nanomaterials. Emphasizing collaboration between industry stakeholders, research institutions, and regulatory bodies is essential to strike a balance between ensuring product quality and fostering a conducive environment for ongoing innovation. By addressing the complexities of standardization, the market can better capitalize on the inherent flexibility of nanotechnology and drive sustainable growth in cancer treatment solutions.

Key Market Trends

Immunotherapy Enhancement

Immunotherapy enhancement is poised to be a driving force behind the growth of the Global Cancer Nanotechnology Market. Nanotechnology offers a transformative platform for augmenting the effectiveness of immunotherapies, which harness the body's immune system to combat cancer. Nanoparticles can be engineered to serve as carriers for immunomodulatory agents, allowing for targeted and controlled release directly within the tumor microenvironment. The precision of nanotechnology facilitates the delivery of immunotherapeutic payloads directly to cancer cells, overcoming challenges associated with systemic administration. Additionally, nanomaterials can be designed to modulate immune responses, enhancing the overall efficacy of immunotherapy treatments. This synergistic combination holds the potential to boost the therapeutic outcomes of immunotherapies, improving patient responses and expanding the scope of applications. In March 2024, researchers from Purdue University announced the development and validation of patent-pending poly(lactic-co-glycolic acid) (PLGA) nanoparticles modified with adenosine triphosphate (ATP) to enhance the effectiveness of immunotherapy against malignant tumors. These nanoparticles are designed to release drugs that trigger immunogenic cell death (ICD) within tumors, which in turn generates tumor antigens and other molecules that attract immune cells to the tumor microenvironment. By attaching ATP to the nanoparticles, the researchers effectively recruit immune cells to the tumor site, thereby boosting the body's anti-tumor immune responses. When combined with an existing immunotherapy drug, the ATP-modified, paclitaxel-loaded nanoparticles successfully eliminated tumors in mice and provided protection against subsequent tumor cell challenges. This development offers a promising advancement in the enhancement of immunotherapy, demonstrating how nanotechnology can be leveraged to improve the precision and efficacy of cancer treatments. By augmenting the immune system's natural response to tumors, these nanoparticles could pave the way for more effective, targeted therapies that minimize side effects and maximize treatment success. Companies investing in the convergence of nanotechnology and immunotherapy are likely to be at the forefront of market growth. As the demand for more effective and personalized cancer treatments continues to rise, the collaboration between nanotechnology and immunotherapy is expected to drive innovation, propel research and development initiatives, and foster the expansion of the Global Cancer Nanotechnology Market.

Multifunctional Nanoparticles

Multifunctional nanoparticles are positioned to drive significant growth in the Global Cancer Nanotechnology Market. These nanoparticles, with their ability to integrate multiple functions into a single platform, offer a versatile and efficient approach to cancer diagnosis and treatment. Engineered to carry therapeutic payloads, imaging agents, and targeting ligands simultaneously, multifunctional nanoparticles enable a comprehensive and targeted approach to cancer management. The integration of therapeutic and diagnostic functionalities within a single nanosystem enhances precision medicine by allowing real-time monitoring of treatment response. This versatility also enables earlier detection through advanced imaging modalities, contributing to improved patient outcomes. The efficiency of drug delivery is heightened, as these nanoparticles can be designed to specifically target cancer cells while minimizing impact on healthy tissues. Companies investing in the development of multifunctional nanoparticles are poised to capitalize on their broad applicability in cancer care. The adaptability of these nanoparticles aligns with the increasing demand for personalized and effective therapeutic solutions. As research and development efforts advance, the synergy between multifunctional nanoparticles and evolving cancer treatment strategies is expected to fuel the growth of the Global Cancer Nanotechnology Market.

Segmental Insights

Application Insights

Based on Application, the Breast Cancer emerged as the fastest growing segment in the global market for Cancer Nanotechnology during the forecast period. Breast cancer is set to be a key growth driver in the global cancer nanotechnology market. As one of the most common and widely diagnosed cancers worldwide, there is a significant demand for innovative and effective treatment options. According to the World Health Organization (WHO), in 2022, 2.3 million women were diagnosed with breast cancer, and 670,000 died from the disease globally. While 99% of breast cancer cases occur in women, approximately 0.5-1% affect men. The WHO's Global Breast Cancer Initiative (GBCI) aims to reduce global breast cancer mortality by 2.5% annually, potentially preventing 2.5 million deaths between 2020 and 2040. Achieving this goal could reduce breast cancer deaths by 25% by 2030 and 40% by 2040 among women under 70.

Nanotechnology presents a promising opportunity for advancing breast cancer treatment, offering tailored solutions to address the complexities of the disease. Nanoparticles can be engineered to specifically target breast cancer cells, delivering therapeutic agents directly to the tumor site with increased precision. This targeted drug delivery not only minimizes harm to healthy tissues but also potentially reduces side effects and improves overall treatment effectiveness. Furthermore, nanotechnology enhances imaging techniques for early breast cancer detection, improving both prognosis and treatment outcomes. As breast cancer research increasingly focuses on personalized and targeted therapies, the integration of nanotechnology into diagnostics and treatment aligns with the evolving landscape of breast cancer care. Companies developing nanotechnology solutions for breast cancer are well-positioned to capitalize on this growing market, driving the expansion of the global cancer nanotechnology sector.

End User Insights

Based on the End User, the Diagnostics emerged as the dominating segment for the global cancer nanotechnology market in 2024. Diagnostics will play a pivotal role in propelling the growth of the Global Cancer Nanotechnology Market. Nanotechnology offers a revolutionary approach to cancer diagnostics, enabling the development of highly sensitive and specific tools for early detection. Nanoparticles can be designed as advanced contrast agents, enhancing the resolution of imaging modalities such as magnetic resonance imaging (MRI) and computed tomography (CT). This heightened precision allows for the detection of cancer at its earliest stages, significantly improving the chances of successful treatment. Moreover, nanotechnology facilitates the creation of liquid biopsy platforms, where nanoscale materials can detect and analyze cancer biomarkers in bodily fluids with unprecedented sensitivity. This non-invasive approach to diagnostics holds great promise for real-time monitoring of cancer progression and treatment response. Companies investing in the intersection of nanotechnology and cancer diagnostics are poised to drive innovation and capture a substantial market share. As healthcare systems worldwide prioritize early detection and personalized medicine, the integration of nanotechnology in diagnostics represents a critical enabler for advancing cancer care. The demand for more accurate, efficient, and non-invasive diagnostic tools positions nanotechnology as a key driver in shaping the future of global cancer diagnostics.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Cancer Nanotechnology Market in 2024. North America is experiencing a growing prevalence of cancer, which is driving demand for innovative and effective treatment solutions. According to the American Cancer Society, excluding non-melanoma skin cancers, over 2 million new cancer cases are expected to be diagnosed in the U.S. in 2025, with more than 618,000 deaths, equating to approximately 1,700 deaths per day. This rising incidence, combined with an aging population, is increasing the need for advanced cancer treatments, including those utilizing nanotechnology, thereby creating a robust market for novel therapies and diagnostic tools.

The region, particularly the United States, benefits from a highly developed healthcare system, featuring cutting-edge medical facilities and a strong network of research institutions. This infrastructure supports the adoption and development of groundbreaking technologies like nanotechnology in cancer care. North America is also a leader in healthcare research and development (R&D), with substantial investments from both government agencies (e.g., the National Institutes of Health, NIH) and private sector companies. These investments drive the development of new nanotechnology-based therapies and diagnostics, accelerating innovation and facilitating the rapid commercialization of these solutions. Home to some of the world's largest and most influential biotech and pharmaceutical companies, North America plays a critical role in advancing nanotechnology-based cancer treatments. Many of these companies are actively engaged in research, clinical trials, and the commercialization of nanotechnology products, further reinforcing the region's leadership. Additionally, regulatory agencies like the U.S. Food and Drug Administration (FDA) and Health Canada provide a strong regulatory framework that facilitates the approval and market entry of new medical technologies. In particular, the FDA has streamlined its approval processes for nanomedicines, enabling quicker availability of cancer treatments based on nanotechnology. North America benefits from strong collaboration between academic institutions, research organizations, and the private sector, fostering continuous innovation in cancer nanotechnology. These partnerships help translate research into clinical applications, ensuring a steady flow of new discoveries into the market. Together, these factors create a favorable ecosystem for the growth of cancer nanotechnology, cementing North America's dominant position in the global market.

Key Market Players

• Abbott Laboratories Ltd.
• GE Healthcare Inc.
• Combimatrix Corporation.
• Mallinckrodt Plc
• Sigma-Tau Pharmaceuticals Inc.
• Merck and Company Inc.
• Pfizer, Inc.
• Nanosphere, Inc. (Luminex Corporation)
• Celgene Corporation
• Teva Pharmaceutical Industries

Report Scope:

In this report, the Global Cancer Nanotechnology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Nanotechnology Market, By Type:

• Nanoparticles
• Nanofibers
• Nanorods
• Graphene
• Nanofluidic Devices
• Others

Cancer Nanotechnology Market, By Application:

• Breast Cancer
• Stomach Cancer
• Lung Cancer
• Others

Cancer Nanotechnology Market, By End User:

• Diagnostics
• Therapeutics
• Theranostics

Cancer Nanotechnology Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Nanotechnology Market.

Available Customizations:

Global Cancer Nanotechnology market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Nanotechnology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Nanoparticles, Nanofibers, Nanorods, Graphene, Nanofluidic Devices, Others)
  • 5.2.2. By Application (Breast Cancer, Stomach Cancer, Lung Cancer, Others)
  • 5.2.3. By End User (Diagnostics, Therapeutics, Theranostics)
  • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 5.2.5. By Company (2024)
• 5.3. Market Map
• 5.3.1 By Type
• 5.3.2 By Application
• 5.3.3 By End User
• 5.3.4 By Region

6. North America Cancer Nanotechnology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Nanoparticles, Nanofibers, Nanorods, Graphene, Nanofluidic Devices, Others)
  • 6.2.2. By Application (Breast Cancer, Stomach Cancer, Lung Cancer, Others)
  • 6.2.3. By End User (Diagnostics, Therapeutics, Theranostics)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cancer Nanotechnology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Cancer Nanotechnology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Cancer Nanotechnology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Cancer Nanotechnology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Nanoparticles, Nanofibers, Nanorods, Graphene, Nanofluidic Devices, Others)
  • 7.2.2. By Application (Breast Cancer, Stomach Cancer, Lung Cancer, Others)
  • 7.2.3. By End User (Diagnostics, Therapeutics, Theranostics)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cancer Nanotechnology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Cancer Nanotechnology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Cancer Nanotechnology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Cancer Nanotechnology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Cancer Nanotechnology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Cancer Nanotechnology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Nanoparticles, Nanofibers, Nanorods, Graphene, Nanofluidic Devices, Others)
  • 8.2.2. By Application (Breast Cancer, Stomach Cancer, Lung Cancer, Others)
  • 8.2.3. By End User (Diagnostics, Therapeutics, Theranostics)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Cancer Nanotechnology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Cancer Nanotechnology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Cancer Nanotechnology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Cancer Nanotechnology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Cancer Nanotechnology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Cancer Nanotechnology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Nanoparticles, Nanofibers, Nanorods, Graphene, Nanofluidic Devices, Others)
  • 9.2.2. By Application (Breast Cancer, Stomach Cancer, Lung Cancer, Others)
  • 9.2.3. By End User (Diagnostics, Therapeutics, Theranostics)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cancer Nanotechnology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Cancer Nanotechnology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Cancer Nanotechnology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Cancer Nanotechnology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Nanoparticles, Nanofibers, Nanorods, Graphene, Nanofluidic Devices, Others)
  • 10.2.2. By Application (Breast Cancer, Stomach Cancer, Lung Cancer, Others)
  • 10.2.3. By End User (Diagnostics, Therapeutics, Theranostics)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cancer Nanotechnology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Cancer Nanotechnology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Cancer Nanotechnology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Global Cancer Nanotechnology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Product Offerings
  • 15.1.3. Recent Developments
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Key Personnel
  • 15.1.6. SWOT Analysis
• 15.2. GE Healthcare Inc.
• 15.3. Combimatrix Corporation.
• 15.4. Mallinckrodt Plc
• 15.5. Sigma-Tau Pharmaceuticals Inc.
• 15.6. Merck and Company Inc.
• 15.7. Pfizer, Inc.
• 15.8. Nanosphere, Inc. (Luminex Corporation)
• 15.9. Celgene Corporation
• 15.10. Teva Pharmaceutical Industries

16. Strategic Recommendations